RBC Capital Markets Upgrades Sartorius Stedim Biotech

RBC Capital Markets has upgraded Sartorius Stedim Biotech to 'Outperform' and raised its price target, citing improved business performance and outlook. The analyst highlighted a shift from currency headwinds to tailwinds and anticipates growth acceleration in 2027. This upgrade is part of a broader positive reassessment of Sartorius AG and its subsidiary, Sartorius Stedim Biotech.